Saniona AB (STO:SANION), a biotechnology company focused on the central nervous system and eating disorders, announced on Monday the establishment of a Scientific Advisory Board (SAB) for the development of Tesomet in PWS (Prader Willi Syndrome).

According to the company, Tesomet has demonstrated reductions in craving for food and weight in the rare genetic eating disorder Prader Willi Syndrome and it is now planning for the final clinical and regulatory programme targeting a billion-dollar market.

Accordingly, Saniona has established a highly esteemed advisory board to oversee the programme and provide guidance for the design of the final phase 2b and phase 3 studies, which are expected to be conducted in the US and Europe over the coming two years.

Saniona's Scientific Advisory Board, which recently met for the first meeting in Copenhagen, comprises of several highly regarded and influential experts from the US and Europe with a profound experience in Prader Willi syndrome, including Tony Holland, MD, CBE – Emeritus Professor of Psychiatry, University of Cambridge, president of the International Prader-Willi Syndrome Organisation; Theresa Strong, PhD - director of Research Programmes, Foundation for Prader-Willi Research; Janice Forster, MD – Child and Adolescent Psychiatrist in private practice in Pittsburgh, PA, specialising in developmental neuropsychiatry and Prader-Willi syndrome and Susanne Blichfeldt, MD - Consultant (Paediatrics), Copenhagen, vice-chair, Clinical & Medical Advisory Board, International Prader-Willi Organisation.

Also, Saniona has extended the ongoing open label study in both Czech Republic and Hungary and the dose has been adjusted to 0.25mg. This last extension of the study will be completed in July 2019.